• Retina/Vitreous

    This prospective, double-masked, randomized clinical trial compared outcomes in 15 patients with AMD treated with bevacizumab to seven patients treated with ranibizumab. At one year, there was no difference in visual and anatomic outcomes between the two groups. The bevacizumab group underwent an average of eight injections while the ranibizumab group underwent a mean of four injections (P=0.001). They conclude that further studies with larger sample sizes are warranted.